Table 2.
Method | AUC | Sensitivity | Specificity | PPV | NPV |
---|---|---|---|---|---|
QP | 0.92 (82–97) | 87 (66–97) | 93 (81–99) | 87 (66–97) | 93 (81–99) |
CER | 0.78* (66–87) | 57* (35–77) | 91 (78–98) | 76 (49–94) | 80 (66–90) |
SLP | 0.82* (71–91) | 87 (66–97) | 68* (52–81) | 59 (41–75) | 91 (75–98) |
INT | 0.75* (63–85) | 83 (61–95) | 68* (52–81) | 58 (39–75) | 88 (72–97) |
Duke | 0.70* (57–80) | 87 (66–97) | 52* (37–68) | 49 (33–65) | 88 (70–98) |
Clinical | 0.78* (66–87) | 83 (61–95) | 73* (57–85) | 61 (42–78) | 89 (74–97) |
p < 0.05 versus QP; statistical comparison of PPV and NPV was not performed. 95% confidence intervals are displayed in parenthesis.